W. Slichenmyer and D. Fry, Anticancer therapy targeting the erbB family of receptor tyrosine kinases, Seminars in Oncology, vol.28, pp.67-79, 2001.
DOI : 10.1016/S0093-7754(01)90284-2

M. Schmidt, B. Lewark, and N. Kohlschmidt, Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing, Breast Cancer Research, vol.7, issue.2, pp.256-266, 2005.
DOI : 10.1186/bcr991

M. Martín, A. Rodríguez-lescure, and A. Ruiz, Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.805-814, 2008.
DOI : 10.1093/jnci/djn151

J. Ross and J. Fletcher, The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy, Oncologist, vol.3, pp.237-252, 1998.

G. Peoples, P. Goedegebuure, R. Smith, D. Linehan, I. Yoshino et al., Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide., Proceedings of the National Academy of Sciences, vol.92, issue.2, pp.432-436, 1995.
DOI : 10.1073/pnas.92.2.432

D. Slamon, L. , B. Shak, and S. , Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.783-792, 2001.
DOI : 10.1056/NEJM200103153441101

R. Nahta and F. Esteva, Herceptin: mechanisms of action and resistance, Cancer Letters, vol.232, issue.2, pp.123-138, 2006.
DOI : 10.1016/j.canlet.2005.01.041

K. Berns, H. Horlings, and B. Hennessy, A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer, Cancer Cell, vol.12, issue.4, pp.395-402, 2007.
DOI : 10.1016/j.ccr.2007.08.030

M. Cobleigh, C. Vogel, and D. Tripathy, Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease, Journal of Clinical Oncology, vol.17, issue.9, pp.2639-2648, 1999.
DOI : 10.1200/JCO.1999.17.9.2639

C. Bengala, C. Zamagni, and P. Pedrazzoli, Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study, British Journal of Cancer, vol.235, issue.7, pp.1016-1020, 2006.
DOI : 10.1200/JCO.2005.02.4091

M. Disis, E. Calenoff, and G. Mclaughlin, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res, vol.54, pp.16-20, 1994.

B. Fisk, T. Blevins, J. Wharton, and C. Ioannides, Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, Journal of Experimental Medicine, vol.181, issue.6, pp.2109-2117, 1995.
DOI : 10.1084/jem.181.6.2109

M. Disis, H. Bernhard, and F. Shiota, Granulocyte-macrophage colonystimulating factor: an effective adjuvant for protein and peptide-based vaccines, Blood, vol.88, pp.202-210, 1996.

C. Huber and T. Wölfel, Immunotherapy of cancer: from vision to standard clinical practice, J Cancer Res Clin Oncol, vol.130, pp.367-374, 2004.

B. Fendly, M. Winget, R. Hudziak, M. Lipari, M. Napier et al., Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product, Cancer Res, vol.50, pp.1550-1558, 1990.

M. Pegram, G. Pauletti, and D. Slamon, Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy, Breast Cancer Research and Treatment, vol.54, issue.1-3, pp.65-77, 1998.
DOI : 10.1023/A:1006111117877

E. Winer and H. Burstein, New Combinations with Herceptin^?? in Metastatic Breast Cancer, Oncology, vol.61, issue.2, pp.50-57, 2001.
DOI : 10.1159/000055402

F. Rilke, M. Colnaghi, and N. Cascinelli, Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors, International Journal of Cancer, vol.49, issue.1, pp.44-49, 1991.
DOI : 10.1002/ijc.2910490109

M. Disis, F. Shiota, and M. Cheever, Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ???self??? tumour antigens, Immunology, vol.126, issue.2, pp.192-199, 1998.
DOI : 10.1016/0165-0378(92)90038-6

N. Nanda and E. Sercarz, Induction of anti-self-immunity to cure cancer, Cell, vol.82, issue.1, pp.13-17, 1995.
DOI : 10.1016/0092-8674(95)90047-0

N. Dakappagari, D. Douglas, P. Triozzi, V. Stevens, and P. Kaumaya, Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine, Cancer Res, vol.60, pp.3782-3789, 2000.

M. Disis, J. Gralow, H. Bernhard, S. Hand, W. Rubin et al., Peptidebased , but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic selfprotein, J Immunol, vol.156, pp.3151-3158, 1996.

M. Disis, T. Gooley, and K. Rinn, Generation of T-Cell Immunity to the HER-2/neu Protein After Active Immunization With HER-2/neu Peptide???Based Vaccines, Journal of Clinical Oncology, vol.20, issue.11, pp.2624-2632, 2002.
DOI : 10.1200/JCO.2002.06.171

A. Concetti, A. Amici, C. Petrelli, A. Tibaldi, M. Provinciali et al., Autoantibody to p185 erbB2/neu oncoprotein by vaccination with xenogenic DNA, Cancer Immunology, Immunotherapy, vol.43, issue.5, pp.307-315, 1996.
DOI : 10.1007/s002620050338

D. Carlo, E. Rovero, S. Boggio, and K. , Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice, Clin Cancer Res, vol.7, pp.830-837, 2001.

S. Pilon, M. Piechocki, and W. Wei, Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody, The Journal of Immunology, vol.167, issue.6, pp.3201-3206, 2001.
DOI : 10.4049/jimmunol.167.6.3201

G. Curigliano, G. Spitaleri, and E. Pietri, Breast cancer vaccines: a clinical reality or fairy tale?, Annals of Oncology, vol.17, issue.5, pp.750-762, 2006.
DOI : 10.1093/annonc/mdj083

P. Lollini, D. Giovanni, C. Pannellini, T. Cavallo, F. Forni et al., Cancer immunoprevention, Future Oncology, vol.60, issue.1, pp.57-66, 2005.
DOI : 10.1002/ijc.11092

M. Seavey, Z. Pan, and P. Maciag, A Novel Human Her-2/neu Chimeric Molecule Expressed by Listeria monocytogenes Can Elicit Potent HLA-A2 Restricted CD8-positive T cell Responses and Impact the Growth and Spread of Her-2/neu-positive Breast Tumors, Clinical Cancer Research, vol.15, issue.3, pp.924-932, 2009.
DOI : 10.1158/1078-0432.CCR-08-2283

J. Holmes, L. Benavides, and J. Gates, Peptide (AE37) Vaccine, Journal of Clinical Oncology, vol.26, issue.20, pp.3426-3433, 2008.
DOI : 10.1200/JCO.2007.15.7842

F. Hodi, Cytotoxic T-Lymphocyte-Associated Antigen-4, Clinical Cancer Research, vol.13, issue.18, pp.5238-5242, 2007.
DOI : 10.1158/1078-0432.CCR-07-0813

A. Dols, J. Smith, and S. Meijer, Vaccination of Women with Metastatic Breast Cancer, Using a Costimulatory Gene (CD80)-Modified, HLA-A2-Matched, Allogeneic, Breast Cancer Cell Line: Clinical and Immunological Results, Human Gene Therapy, vol.14, issue.11, pp.1117-1123, 2003.
DOI : 10.1089/104303403322124828

A. Dols, S. Meijer, and H. Hu, Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells, Journal of Immunotherapy, vol.26, issue.2, pp.163-170, 2003.
DOI : 10.1097/00002371-200303000-00009

P. Kim, T. Armstrong, and H. Song, Antibody association with HER-2/neu???targeted vaccine enhances CD8+ T cell responses in mice through Fc-mediated activation of DCs, Journal of Clinical Investigation, vol.118, issue.5, pp.1700-1711, 2008.
DOI : 10.1172/JCI34333

J. Park, M. Melisko, L. Esserman, L. Jones, J. Wollan et al., Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 ???Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2???Overexpressing Breast Cancer, Journal of Clinical Oncology, vol.25, issue.24, pp.3680-3687, 2007.
DOI : 10.1200/JCO.2006.10.5718

Y. Sakai, B. Morrison, and J. Burke, Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice, Cancer Research, vol.64, issue.21, pp.8022-8028, 2004.
DOI : 10.1158/0008-5472.CAN-03-3442

Y. Chen, P. Emtage, and Q. Zhu, Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12, Gene Therapy, vol.8, issue.4, pp.316-323, 2001.
DOI : 10.1038/sj.gt.3301396

Z. Chen, H. Huang, and T. Chang, Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor, Cancer Gene Therapy, vol.9, issue.9, pp.778-786, 2002.
DOI : 10.1038/sj.cgt.7700498

M. Campbell, S. Qu, S. Wells, H. Sugandha, and R. Jensen, An adenoviral vector containing an arg???gly???asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression, Cancer Gene Therapy, vol.10, issue.7, pp.559-570, 2003.
DOI : 10.1038/sj.cgt.7700599

S. Sas, T. Chan, A. Sami, A. El-gayed, and J. Xiang, Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice, Cancer Gene Therapy, vol.60, issue.10, pp.655-666, 2008.
DOI : 10.1158/0008-5472.CAN-04-1081

T. Chan, A. Sami, A. El-gayed, X. Guo, and J. Xiang, HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination, Gene Therapy, vol.4, issue.19, pp.1391-1402, 2006.
DOI : 10.1038/sj.gt.3302797

C. Viehl, M. Becker-hapak, and J. Lewis, A Tat Fusion Protein???Based Tumor Vaccine for Breast Cancer, Annals of Surgical Oncology, vol.198, issue.Suppl 2, pp.517-525, 2005.
DOI : 10.1245/ASO.2005.06.028

P. Brossart, S. Wirths, G. Stuhler, V. Reichardt, L. Kanz et al., Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, vol.96, pp.3102-3108, 2000.

M. Disis, J. Strickler, and D. Wallace, Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine, Journal of Clinical Oncology, vol.26, issue.15_suppl, p.3015, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.3015

D. Webster, J. Waisman, and B. Macleod, A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab, 2006.

E. Mittendorf, J. Holmes, S. Ponniah, and G. Peoples, The E75 HER2/neu peptide vaccine, Cancer Immunology, Immunotherapy, vol.13, issue.10, pp.1511-1521, 2008.
DOI : 10.1007/s00262-008-0540-3

J. Lustgarten, M. Theobald, and C. Labadie, Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8, Human Immunology, vol.52, issue.2, pp.109-118, 1997.
DOI : 10.1016/S0198-8859(96)00292-3

B. Anderson, G. Peoples, J. Murray, M. Gillogly, D. Gershenson et al., Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals, Clin Cancer Res, vol.6, pp.4192-4200, 2000.

K. Knutson, K. Schiffman, M. Cheever, and M. Disis, Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity, Clin Cancer Res, vol.8, pp.1014-1018, 2002.

J. Murray, M. Gillogly, and D. Przepiorka, Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer, Clin Cancer Res, vol.8, pp.3407-3418, 2002.

T. Zaks and S. Rosenberg, Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Cancer Res, vol.58, pp.4902-4908, 1998.

G. Peoples, J. Gurney, and M. Hueman, (E75) Vaccine to Prevent Recurrence in High-Risk Breast Cancer Patients, Journal of Clinical Oncology, vol.23, issue.30, pp.7536-7545, 2005.
DOI : 10.1200/JCO.2005.03.047

G. Peoples, J. Holmes, and M. Hueman, Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, Clinical Cancer Research, vol.14, issue.3, pp.797-803, 2008.
DOI : 10.1158/1078-0432.CCR-07-1448

M. Hueman, A. Stojadinovic, and C. Storrer, Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine???, Breast Cancer Research and Treatment, vol.25, issue.Suppl 11, pp.17-29, 2006.
DOI : 10.1007/s10549-005-9108-5

J. Shimizu, S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity, J Immunol, vol.163, pp.5211-5218, 1999.

L. Benavides, J. Gates, and M. Carmichael, The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, Clinical Cancer Research, vol.15, issue.8, pp.2895-2904, 2009.
DOI : 10.1158/1078-0432.CCR-08-1126

E. Mittendorf, C. Storrer, C. Shriver, S. Ponniah, and G. Peoples, Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer, Annals of Surgical Oncology, vol.24, issue.8, pp.1085-1098, 2006.
DOI : 10.1245/ASO.2006.03.069

E. Mittendorf, C. Storrer, and R. Foley, -derived peptide GP2 for use in a peptide-based breast cancer vaccine trial, Cancer, vol.22, issue.11, pp.2309-2317, 2006.
DOI : 10.1002/cncr.21849
URL : https://hal.archives-ouvertes.fr/hal-00550172

E. Lekka, A. Gritzapis, and S. Perez, Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy, Cancer Immunology, Immunotherapy, vol.106, issue.11, pp.715-727, 2010.
DOI : 10.1007/s00262-009-0791-7

Y. Yip, G. Smith, J. Koch, S. Dübel, and R. Ward, Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design, The Journal of Immunology, vol.166, issue.8, pp.5271-5278, 2001.
DOI : 10.4049/jimmunol.166.8.5271

N. Dakappagari, J. Pyles, R. Parihar, W. Carson, D. Young et al., A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses, The Journal of Immunology, vol.170, issue.8, pp.4242-4253, 2003.
DOI : 10.4049/jimmunol.170.8.4242

H. Cho, K. Mason, and K. Ramyar, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, vol.24, issue.6924, pp.756-760, 2003.
DOI : 10.1038/nature01392

J. Garrett, S. Rawale, and S. Allen, Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu, The Journal of Immunology, vol.178, issue.11, pp.7120-7131, 2007.
DOI : 10.4049/jimmunol.178.11.7120

A. Riemer, M. Klinger, and S. Wagner, Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu, The Journal of Immunology, vol.173, issue.1, pp.394-401, 2004.
DOI : 10.4049/jimmunol.173.1.394

J. Jasinska, S. Wagner, and C. Radauer, Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu, International Journal of Cancer, vol.194, issue.6, pp.976-983, 2003.
DOI : 10.1002/ijc.11485

S. Wagner, J. Jasinska, and H. Breiteneder, Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice, Breast Cancer Research and Treatment, vol.4, issue.1, pp.29-38, 2007.
DOI : 10.1007/s10549-006-9469-4

K. Azuma, S. Shichijo, H. Shomura, S. Matsueda, T. Fujii et al., Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients, Breast Cancer Research and Treatment, vol.94, issue.1, pp.19-29, 2004.
DOI : 10.1023/B:BREA.0000032920.95410.63

B. Seliger, C. Harders, and S. Lohmann, Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts, European Journal of Immunology, vol.261, issue.1, pp.122-133, 1998.
DOI : 10.1002/(SICI)1521-4141(199801)28:01<122::AID-IMMU122>3.0.CO;2-F

P. Schrier, R. Versteeg, L. Peltenburg, A. Plomp, . Van-'t et al., Sensitivity of melanoma cell lines to natural killer cells: a role for oncogenemodulated HLA class I expression?, Semin Cancer Biol, vol.2, pp.73-83, 1991.

A. Choudhury, C. J. Parapuram, and S. , Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines, International Journal of Cancer, vol.296, issue.1, pp.71-77, 2004.
DOI : 10.1002/ijc.11497

F. Herrmann, H. Lehr, and I. Drexler, HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway, Cancer Research, vol.64, issue.1, pp.215-220, 2004.
DOI : 10.1158/0008-5472.CAN-2522-2

S. Vertuani, C. Triulzi, and A. Roos, HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice, Cancer Immunology, Immunotherapy, vol.21, issue.5, pp.653-664, 2009.
DOI : 10.1007/s00262-008-0587-1

S. Limentani, T. Dorval, and S. White, Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer, Journal of Clinical Oncology, vol.23, issue.16_suppl, p.520, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.2520

S. Kitano, S. Kageyama, and Y. Nagata, HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan, Clinical Cancer Research, vol.12, issue.24, pp.7397-7405, 2006.
DOI : 10.1158/1078-0432.CCR-06-1546

S. Kageyama, S. Kitano, and M. Hirayama, Humoral immune responses in patients vaccinated with 1???146 HER2 protein complexed with cholesteryl pullulan nanogel, Cancer Science, vol.88, issue.3, pp.601-607, 2008.
DOI : 10.1158/1078-0432.CCR-03-0706

R. Baral, A. Sherrat, R. Das, K. Foon, and M. Bhattacharya-chatterjee, Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu, International Journal of Cancer, vol.77, issue.1, pp.88-95, 2001.
DOI : 10.1002/1097-0215(200102)9999:9999<::AID-IJC1148>3.0.CO;2-9

K. Mohanty, A. Saha, and S. Pal, Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu, Breast Cancer Research and Treatment, vol.12, issue.1, pp.1-11, 2007.
DOI : 10.1007/s10549-006-9391-9

S. Pal, A. Saha, and K. Mohanty, Generation of Her-2/neu vaccine utilizing idiotypic network cascade, Cancer Biology & Therapy, vol.6, issue.12, pp.1916-1925, 2007.
DOI : 10.4161/cbt.6.12.4967

A. Saha and S. Chatterjee, Dendritic cells pulsed with an anti-idiotype antibody mimicking Her-2/neu induced protective antitumor immunity in two lines of Her-2/neu transgenic mice, Cellular Immunology, vol.263, issue.1, 2010.
DOI : 10.1016/j.cellimm.2010.02.010

M. Coelho, P. Gauthier, M. Pugnière, F. Roquet, A. Pèlegrin et al., Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice, British Journal of Cancer, vol.12, issue.10, pp.2032-2041, 2004.
DOI : 10.1038/sj.bjc.6601825

N. Alvarez-rueda, M. Ladjemi, and G. Béhar, A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy, Vaccine, vol.27, issue.35, pp.4826-4833, 2009.
DOI : 10.1016/j.vaccine.2009.05.067
URL : https://hal.archives-ouvertes.fr/hal-00414283

M. Rescigno, F. Avogadri, and G. Curigliano, Challenges and prospects of immunotherapy as cancer treatment, Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, vol.1776, issue.1, pp.108-123, 2007.
DOI : 10.1016/j.bbcan.2007.07.003

A. Mantovani, A. Sica, S. Sozzani, P. Allavena, A. Vecchi et al., The chemokine system in diverse forms of macrophage activation and polarization, Trends in Immunology, vol.25, issue.12, pp.677-686, 2004.
DOI : 10.1016/j.it.2004.09.015

P. Kalinski, Y. Nakamura, P. Watchmaker, A. Giermasz, R. Muthuswamy et al., Helper Roles of NK and CD8⁺ T Cells in the Induction of Tumor Immunity Polarized Dendritic Cells as Cancer Vaccines, Immunologic Research, vol.36, issue.1-3, pp.137-146, 2006.
DOI : 10.1385/IR:36:1:137

A. Nowak, R. Lake, and B. Robinson, Combined chemoimmunotherapy of solid tumours: Improving vaccines?, Advanced Drug Delivery Reviews, vol.58, issue.8, pp.975-990, 2006.
DOI : 10.1016/j.addr.2006.04.002

R. Lake and B. Robinson, Opinion: Immunotherapy and chemotherapy ??? a practical partnership, Nature Reviews Cancer, vol.161, issue.5, pp.397-405, 2005.
DOI : 10.1084/jem.145.2.275

A. Nowak, R. Lake, and A. Marzo, Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells, The Journal of Immunology, vol.170, issue.10, pp.4905-4913, 2003.
DOI : 10.4049/jimmunol.170.10.4905

P. Rovere, C. Vallinoto, and A. Bondanza, Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function, J Immunol, vol.161, pp.4467-4471, 1998.

M. Lutsiak, R. Semnani, D. Pascalis, R. Kashmiri, S. Schlom et al., Inhibition of CD4+25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide, Blood, vol.105, issue.7, pp.2862-2868, 2005.
DOI : 10.1182/blood-2004-06-2410

M. Pegram, S. Hsu, and G. Lewis, Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers, Oncogene, vol.18, issue.13, pp.2241-2251, 1999.
DOI : 10.1038/sj.onc.1202526

L. Emens, J. Asquith, and J. Leatherman, Timed Sequential Treatment With Cyclophosphamide, Doxorubicin, and an Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor???Secreting Breast Tumor Vaccine: A Chemotherapy Dose-Ranging Factorial Study of Safety and Immune Activation, Journal of Clinical Oncology, vol.27, issue.35, pp.5911-5918, 2009.
DOI : 10.1200/JCO.2009.23.3494

M. Ellis, A. Coop, and B. Singh, Letrozole Is More Effective Neoadjuvant Endocrine Therapy Than Tamoxifen for ErbB-1??? and/or ErbB-2???Positive, Estrogen Receptor???Positive Primary Breast Cancer: Evidence From a Phase III Randomized Trial, Journal of Clinical Oncology, vol.19, issue.18, pp.3808-3816, 2001.
DOI : 10.1200/JCO.2001.19.18.3808

E. Reits, J. Hodge, and C. Herberts, Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy, The Journal of Experimental Medicine, vol.123, issue.5, pp.1259-1271, 2006.
DOI : 10.1126/science.274.5284.94

B. Zhang, H. Li, L. Guo, D. Yan, J. Liu et al., Application of 64-slice helical CT in screening of coronary artery heart disease among apparently healthy people: preliminary experience, Zhonghua Yi Xue Za Zhi, vol.87, pp.556-558, 2007.

N. Nesslinger, R. Sahota, and B. Stone, Standard Treatments Induce Antigen-Specific Immune Responses in Prostate Cancer, Clinical Cancer Research, vol.13, issue.5, pp.1493-1502, 2007.
DOI : 10.1158/1078-0432.CCR-06-1772

M. Disis, D. Wallace, and T. Gooley, -Specific Vaccination in Patients With Metastatic Breast Cancer, Journal of Clinical Oncology, vol.27, issue.28, pp.4685-4692, 2009.
DOI : 10.1200/JCO.2008.20.6789
URL : https://hal.archives-ouvertes.fr/hal-01440327

A. Coveler, V. Goodell, and D. Webster, Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity, Breast Cancer Research and Treatment, vol.24, issue.1, pp.95-100, 2009.
DOI : 10.1007/s10549-008-9910-y

M. Morse, J. Wei, and Z. Hartman, Synergism from combined immunologic and pharmacologic inhibition of HER2 in vivo, Int J Cancer, 2010.

D. Munn, M. Sharma, and D. Hou, Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes, Journal of Clinical Investigation, vol.114, issue.2, pp.280-290, 2004.
DOI : 10.1172/JCI200421583

M. Friberg, R. Jennings, and M. Alsarraj, Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection, International Journal of Cancer, vol.8, issue.2, pp.151-155, 2002.
DOI : 10.1002/ijc.10645

P. Kali?ski, P. Vieira, J. Schuitemaker, E. De-jong, and M. Kapsenberg, Prostaglandin E2 is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer, Blood, vol.97, issue.11, pp.3466-3469, 2001.
DOI : 10.1182/blood.V97.11.3466

B. Johnson, T. Clay, A. Hobeika, H. Lyerly, and M. Morse, Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy, Expert Opinion on Biological Therapy, vol.96, issue.4, pp.449-460, 2007.
DOI : 10.1158/0008-5472.CAN-06-1690

R. Pañares and A. Garcia, Bevacizumab in the management of solid tumors, Expert Review of Anticancer Therapy, vol.7, issue.4, pp.433-445, 2007.
DOI : 10.1586/14737140.7.4.433

H. Fakhrai, O. Dorigo, and D. Shawler, Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy., Proceedings of the National Academy of Sciences, vol.93, issue.7, pp.2909-2914, 1996.
DOI : 10.1073/pnas.93.7.2909

M. Smyth, K. Takeda, Y. Hayakawa, J. Peschon, M. Van-den-brink et al., Nature's TRAIL???On a Path to Cancer Immunotherapy, Immunity, vol.18, issue.1, pp.1-6, 2003.
DOI : 10.1016/S1074-7613(02)00502-2

K. Takeda, J. Stagg, H. Yagita, K. Okumura, and M. Smyth, Targeting death-inducing receptors in cancer therapy, Oncogene, vol.62, issue.25, pp.3745-3757, 2007.
DOI : 10.1158/0008-5472.CAN-04-1088

J. Stagg, J. Sharkey, and S. Pommey, Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response, Proceedings of the National Academy of Sciences, vol.105, issue.42, pp.16254-16259, 2008.
DOI : 10.1073/pnas.0806849105

F. Hodi, M. Mihm, and R. Soiffer, Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients, Proceedings of the National Academy of Sciences, vol.100, issue.8, pp.4712-4717, 2003.
DOI : 10.1073/pnas.0830997100

F. Hodi, M. Butler, and D. Oble, Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients, Proceedings of the National Academy of Sciences, vol.105, issue.8, pp.3005-3010, 2008.
DOI : 10.1073/pnas.0712237105

A. Sica and V. Bronte, Altered macrophage differentiation and immune dysfunction in tumor development, Journal of Clinical Investigation, vol.117, issue.5, pp.1155-1166, 2007.
DOI : 10.1172/JCI31422

P. Kiewe and E. Thiel, Ertumaxomab: a trifunctional antibody for breast cancer treatment, Expert Opinion on Investigational Drugs, vol.61, issue.10, pp.1553-1558, 2008.
DOI : 10.1089/scd.1.1995.4.409